Compare MHD & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MHD | FLGT |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.9M | 525.3M |
| IPO Year | N/A | 2016 |
| Metric | MHD | FLGT |
|---|---|---|
| Price | $11.69 | $15.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 440.6K | ★ 663.1K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | N/A | $12.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.79 | $13.46 |
| 52 Week High | $12.05 | $31.04 |
| Indicator | MHD | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 40.50 |
| Support Level | $11.63 | $15.39 |
| Resistance Level | $11.80 | $16.85 |
| Average True Range (ATR) | 0.12 | 0.61 |
| MACD | 0.03 | 0.33 |
| Stochastic Oscillator | 96.36 | 43.50 |
Blackrock Muniholdings Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The fund mainly invests its managed assets in municipal bonds rated investment grade or, if unrated, are deemed to be of comparable quality by the investment adviser at the time of investment. Its investment portfolio is mainly comprised of long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.